Risk factors for piperacillin/tazobactam resistance in extended-spectrum beta-lactamase (ESBL) producing organisms
Phase of Trial: Phase III
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Piperacillin/tazobactam (Primary)
- Indications Enterobacteriaceae infections
- Focus Therapeutic Use
- 09 Jun 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2025.
- 09 Jun 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2025.
- 09 Jun 2017 Status changed from active, no longer recruiting to recruiting.